

Carolina L Haass-Koffler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5093195/publications.pdf>

Version: 2024-02-01

43
papers

876
citations

623734

14
h-index

501196

28
g-index

45
all docs

45
docs citations

45
times ranked

1157
citing authors

#	ARTICLE	IF	CITATIONS
1	The Amygdala Noradrenergic System Is Compromised With Alcohol Use Disorder. <i>Biological Psychiatry</i> , 2022, 91, 1008-1018.	1.3	18
2	Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies. <i>Neuropsychopharmacology</i> , 2022, 47, 2111-2122.	5.4	4
3	Brief Report: Relationship Between Cotinine Levels and Peripheral Endogenous Concentrations of Oxytocin, β -Endorphin, and Orexin in Individuals With Both Alcohol and Nicotine Use Disorders. <i>American Journal on Addictions</i> , 2021, 30, 88-91.	1.4	5
4	A Combined Alcohol and Smoking Cue-Reactivity Paradigm in People Who Drink Heavily and Smoke Cigarettes: Preliminary Findings. <i>Alcohol and Alcoholism</i> , 2021, 56, 47-56.	1.6	2
5	Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 464-476.	2.1	11
6	Association of Substance Use With Behavioral Adherence to Centers for Disease Control and Prevention Guidelines for COVID-19 Mitigation: Cross-sectional Web-Based Survey. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e29319.	2.6	13
7	Randomized controlled trials for alcohol use disorder during the COVID-19 pandemic. <i>Alcohol</i> , 2021, 92, 21-24.	1.7	1
8	Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, , 1-9.	2.1	1
9	An inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder. <i>Psychopharmacology</i> , 2021, , 1.	3.1	4
10	Corticotropin Releasing Factor Binding Protein as a Novel Target to Restore Brain Homeostasis: Lessons Learned From Alcohol Use Disorder Research. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 786855.	2.0	7
11	Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations. <i>Neurotherapeutics</i> , 2020, 17, 100-104.	4.4	9
12	New Microglial Mechanisms Revealed in Alcohol Use Disorder: How Does That Translate?. <i>Biological Psychiatry</i> , 2020, 88, 893-895.	1.3	3
13	Differences in Sociodemographic and Alcohol-Related Clinical Characteristics Between Treatment Seekers and Nontreatment Seekers and Their Role in Predicting Outcomes in the COMBINE Study for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2097-2108.	2.4	11
14	Protein Tyrosine Phosphatase β and Alcohol Use Disorder: A Commentary. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1189-1191.	2.4	0
15	Alcohol Tolerance in Human Laboratory Studies for Development of Medications to treat Alcohol Use Disorder. <i>Alcohol and Alcoholism</i> , 2020, 55, 129-135.	1.6	11
16	Translational Research in the Neurobiological Mechanisms of Alcohol and Substance Use Disorders. <i>Neurotherapeutics</i> , 2020, 17, 1-3.	4.4	1
17	Translational dynamics of alcohol tolerance of preclinical models and human laboratory studies.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 417-425.	1.8	2
18	Intravenous administration of ghrelin increases serum cortisol and aldosterone concentrations in heavy-drinking alcohol-dependent individuals: Results from a double-blind, placebo-controlled human laboratory study. <i>Neuropharmacology</i> , 2019, 158, 107711.	4.1	11

#	ARTICLE	IF	CITATIONS
19	Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?. <i>Alcohol and Alcoholism</i> , 2019, 54, 497-502.	1.6	8
20	Noradrenergic targets for the treatment of alcohol use disorder. <i>Psychopharmacology</i> , 2018, 235, 1625-1634.	3.1	51
21	Opioid use and stigma: The role of gender, language and precipitating events. <i>Drug and Alcohol Dependence</i> , 2018, 185, 339-346.	3.2	120
22	Administration of the metabotropic glutamate receptor subtype 5 allosteric modulator GET 73 with alcohol: A translational study in rats and humans. <i>Journal of Psychopharmacology</i> , 2018, 32, 163-173.	4.0	10
23	Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. <i>Alcohol and Alcoholism</i> , 2018, 53, 268-276.	1.6	24
24	The corticotropin releasing factor binding protein: A strange case of Dr. Jekyll and Mr. Hyde in the stress system?. <i>Alcohol</i> , 2018, 72, 3-8.	1.7	7
25	Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?. <i>Journal of Psychopharmacology</i> , 2017, 31, 812-818.	4.0	10
26	A chimeric approach to evaluate the role of corticotropin releasing factor in alcohol use disorder. <i>Alcohol</i> , 2017, 60, 222-223.	1.7	0
27	Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. <i>Drug and Alcohol Dependence</i> , 2017, 177, 23-28.	3.2	38
28	Dataset for Phase I randomized clinical trial for safety and tolerability of GET 73 in single and repeated ascending doses including preliminary pharmacokinetic parameters. <i>Data in Brief</i> , 2017, 15, 407-413.	1.0	13
29	A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, 78-85.	4.0	29
30	S08-2TOWARDS PERSONALIZED TREATMENTS FOR ALCOHOL USE DISORDER: A FOCUS ON ALPHA-1 BLOCKADE. <i>Alcohol and Alcoholism</i> , 2017, 52, i4-i30.	1.6	0
31	Role of the α_1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. <i>Addiction Biology</i> , 2016, 21, 904-914.	2.6	58
32	Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw048.	2.1	11
33	Relationship Between the Thyroid Axis and Alcohol Craving. <i>Alcohol and Alcoholism</i> , 2015, 50, 24-29.	1.6	19
34	Effects of Idazoxan on Alcohol Pharmacokinetics and Intoxication: A Preliminary Human Laboratory Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 594-602.	2.4	12
35	Ondansetron Reduces Naturalistic Drinking in Nontreatment-Seeking Alcohol-Dependent Individuals with the LL ϵ^2 -HTTLPR Genotype: A Laboratory Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2014, 38, 1567-1574.	2.4	31
36	Pharmacological Approaches to Reducing Craving in Patients with Alcohol Use Disorders. <i>CNS Drugs</i> , 2014, 28, 343-360.	5.9	65

#	ARTICLE	IF	CITATIONS
37	Pharmacotherapy for alcoholic patients with alcoholic liver disease. American Journal of Health-System Pharmacy, 2014, 71, 1265-1276.	1.0	42
38	Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: Exploratory findings. Alcohol, 2014, 48, 515-522.	1.7	19
39	Bacchus by Caravaggio as the Visual Diagnosis of Alcohol Use Disorder from the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Frontiers in Psychiatry, 2013, 4, 86.	2.6	9
40	The $\alpha 5$ Subunit Regulates the Expression and Function of $\alpha 4^*$ -Containing Neuronal Nicotinic Acetylcholine Receptors in the Ventral-Tegmental Area. PLoS ONE, 2013, 8, e68300.	2.5	36
41	Mifepristone in the Central Nucleus of the Amygdala Reduces Yohimbine Stress-Induced Reinstatement of Ethanol-Seeking. Neuropsychopharmacology, 2012, 37, 906-918.	5.4	89
42	An Analytical Tool that Quantifies Cellular Morphology Changes from Three-dimensional Fluorescence Images. Journal of Visualized Experiments, 2012, , e4233.	0.3	13
43	Stress and addiction: contribution of the corticotropin releasing factor (CRF) system in neuroplasticity. Frontiers in Molecular Neuroscience, 2012, 5, 91.	2.9	48